Zhang Yuemiao, Gao Wen, Cheng Hong, Zhang Xuezhi, Hu Fulian
Department of Integrated TCM & Western Medicine, Peking University First Hospital, Beijing, China.
Helicobacter. 2014 Oct;19(5):382-6. doi: 10.1111/hel.12143. Epub 2014 May 21.
Eradication rate of Helicobacter pylori decreases worldwide, while antibiotics resistance rates of H. pylori increase rapidly in recent years. In most cases, H. pylori would be resistant to clarithromycin, metronidazole, and quinolone if these antibiotics had been used as component of eradication regimen. H. pylori strains resistant to both tetracycline and furazolidone are rare. The aim of our study was to evaluate efficacy and side effects of tetracycline- and furazolidone-containing quadruple regimen as rescue treatment.
Patients with H. pylori infection given RTFB (rabeprazole 20 mg b.i.d. + tetracycline 750 mg b.i.d. +furazolidone 100 mg b.i.d. + colloidal bismuth subcitrate 200 mg b.i.d.) regimen for 14 days as rescue treatment were enrolled in this retrospective study. Eradication status was evaluated by (13) C-urea breath test, and side effects were collected.
One hundred and nine patients were enrolled. The intention-to-treat eradication rate was 91.74% (100 of 109) and 95.24% (100 of 105) per protocol analysis. Side effects including fever, palpitation, and skin rash occurred in 35 patients.
The 14-day tetracycline- and furazolidone-containing quadruple regimen can achieve a relatively high eradication rate as rescue treatment. Some side effects including fever may occur during the treatment.
全球范围内幽门螺杆菌的根除率呈下降趋势，而近年来幽门螺杆菌的抗生素耐药率迅速上升。在大多数情况下，如果将克拉霉素、甲硝唑和喹诺酮类抗生素用作根除方案的组成部分，幽门螺杆菌会对其产生耐药性。对四环素和呋喃唑酮均耐药的幽门螺杆菌菌株较为罕见。本研究的目的是评估含四环素和呋喃唑酮的四联方案作为补救治疗的疗效和副作用。
本回顾性研究纳入了接受RTFB（雷贝拉唑20mg，每日2次+四环素750mg，每日2次+呋喃唑酮100mg，每日2次+枸橼酸铋钾200mg，每日2次）方案进行14天补救治疗的幽门螺杆菌感染患者。通过碳-13尿素呼气试验评估根除情况，并收集副作用。
共纳入109例患者。意向性分析的根除率为91.74%（109例中的100例），符合方案分析的根除率为95.24%（105例中的100例）。35例患者出现了包括发热、心悸和皮疹在内的副作用。
含四环素和呋喃唑酮的14天四联方案作为补救治疗可实现相对较高的根除率。治疗期间可能会出现包括发热在内的一些副作用。
